ArticleArchives of toxicology2026
2-Amino-3-methylimadazo[4,5-f]quinoline (IQ) induces cytochrome P450 1A through the canonical AhR-XRE pathway in human hepatocytes.
Article in Archives of toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Heterocyclic aromatic amines (HAAs) are procarcinogens formed during the cooking of meat and fish and could potentially contribute to hepatocellular carcinoma. Although several HAAs are classified as possible or probable human carcinogens, most mechanistic studies have relied on rodent models, despite well-documented interspecies differences in HAA bioactivation by cytochrome P450 (CYP) isoforms. In this study, we investigated the regulation of CYP1A by the HAA 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) using complementary primary human hepatocytes and Hepoid® with HepaRG cells, a long-term 3D liver spheroid model. IQ at concentrations ranging from 0.1 to 20 µM strongly induced CYP1A1 and CYP1A2 expression and enzymatic activity following acute and chronic exposure, whereas other major hepatic CYP isoforms remained unaffected. This response was specific to IQ among other HAAs tested and to human hepatocytes and persisted for up to 28 days in 3D spheroids. IQ-induced CYP1A expression required transcriptional activation and involved the aryl hydrocarbon receptor (AhR). Using complementary pharmacological and genetic approaches, luciferase reporter assays and ligand-binding assays, we demonstrate that IQ is a direct AhR ligand that activates the canonical AhR-xenobiotic response element (XRE) signaling pathway in human hepatocytes. These findings indicate that IQ is a potent and selective inducer of CYP1A through the AhR and induces a sustained human-specific response upon repeated treatment. Persistent CYP1A induction and AhR activation may enhance the bioactivation of IQ and other co-occurring CYP1A substrates, highlighting the value of long-term human-relevant models to improve risk assessment of chemical carcinogens.
Indexed as
Identifiers
42834146What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.